In vivo activity of pyrimidine-dispirotripiperaziniumin in the male guinea pig model of genital herpes

ABSTRACT Feto-placental infections represent a major cause of pregnancy complications, and yet the underlying molecular and cellular mechanisms of vertical transmission are poorly understood. Listeria monocytogenes, a facultative intracellular pathogen, is one of a group of pathogens that are known to cause feto-placental infections in humans and other mammals. The purpose of this study was to evaluate possible mechanisms of vertical transmission of L. monocytogenes. Humans and guinea pigs have a hemochorial placenta, where a single layer of fetally derived trophoblasts separates maternal from fetal circulation. We characterized L. monocytogenes infection of the feto-placental unit in a pregnant guinea pig model and in primary human trophoblasts and trophoblast-derived cell lines. The clinical manifestations of listeriosis in the pregnant guinea pigs and the tropism of L. monocytogenes to the guinea pig placenta resembled those in humans. Trophoblast cell culture systems were permissive for listerial growth and cell-to-cell spread and revealed that L. monocytogenes deficient in internalin A, a virulence factor that mediates invasion of nonphagocytic cells, was 100-fold defective in invasion. However, crossing of the feto-placental barrier in the guinea pig model was independent of internalin A, suggesting a negligible role for internalin-mediated direct invasion of trophoblasts in vivo. Further understanding of vertical transmission of L. monocytogenes will help in designing more effective means of treatment and disease prevention.

Download Full-text

Genital Herpes: Pathogenesis and Chemotherapy in the Guinea Pig Model

Clinical Infectious Diseases ◽

10.1093/clinids/6.1.33 ◽

1984 ◽

Vol 6 (1) ◽

pp. 33-50 ◽

Cited By ~ 29

Author(s):

G. D. Hsiung ◽

D. R. Mayo ◽

H. L. Lucia ◽

M. L. Landry

Keyword(s):

Guinea Pig ◽

Genital Herpes ◽

Pig Model ◽

Guinea Pig Model

Download Full-text

Pathogenesis of drug resistant clinical HSV-2 isolates in the guinea pig model of genital herpes

Antiviral Research ◽

10.1016/0166-3542(95)94905-h ◽

1995 ◽

Vol 26 (3) ◽

pp. A335

Keyword(s):

Guinea Pig ◽

Genital Herpes ◽

Pig Model ◽

Drug Resistant ◽

Guinea Pig Model

Download Full-text

The ascorbate-deficient guinea pig model of shigellosis allows the study of the entire Shigella life cycle

10.1101/2020.08.28.270074 ◽

2020 ◽

Author(s):

Antonin C André ◽

Céline Mulet ◽

Mark C Anderson ◽

Louise Injarabian ◽

Achim Buch ◽

...

Keyword(s):

Animal Model ◽

Life Cycle ◽

Guinea Pig ◽

Guinea Pigs ◽

Colonic Mucosa ◽

Extended Period ◽

Pig Model ◽

Suitable Animal Model ◽

Guinea Pig Model

AbstractShigella spp. are the causative agents of bacillary dysentery or shigellosis, mainly in children living in developing countries. The study of Shigella entire life cycle in vivo and the evaluation of vaccine candidates’ protection efficacy have been hampered by the lack of a suitable animal model of infection (1). None of the ones evaluated so far (mouse, rabbit, guinea pig) allows to recapitulate shigellosis symptoms upon Shigella oral challenge. Historical reports suggest that dysentery and scurvy are both metabolic diseases associated with ascorbate-deficiency. Mammals which are susceptible to Shigella infection (humans, non-human primates and guinea pigs) are the lonely ones which are unable to synthesize ascorbate. We optimized a low-ascorbate diet to induce moderate ascorbate-deficiency but not scurvy in guinea pigs (Ascplasma conc.=1.6 μM vs 36 μM with optimal ascorbate supply). We demonstrated that moderate ascorbate-deficiency increases shigellosis severity during extended period of time (up to 48h) with all strains tested (Shigella flexneri 5a and 2a, Shigella sonnei). At late time-points, a massive influx of neutrophils was observed both within the disrupted colonic mucosa and in the luminal compartment, although Shigella remains able to disseminate deep into the organ to reach the sub-mucosal layer and the bloodstream. This new model of shigellosis opens new doors for the study both of Shigella infection strategy and innate and adaptive immune responses to Shigella infection. It may be also of a great interest to study the virulence of other pathogen for which no suitable animal model of infection is available (Vibrio cholerae, Yersinia pestis, Mycobacterium tuberculosis or Campylobacter jejuni, among others).SignificanceThe study of Shigella virulence cycle in vivo has been hampered by the lack of a suitable animal model, which would allow the colonic mucosa infection upon oral challenge. Based on historical reports and physiological aspects, it was suggested that ascorbate-deficiency may stand as a new dysentery risk-factor. To test this hypothesis, we set up a new ascorbate-deficient guinea pig model and demonstrated for the first time that the Shigella infectious process occurred for extended period of time (up to 48h) and demonstrated that shigellosis severity was higher in ascorbate-deficient animal. Ascorbate-deficient guinea pig model of infection may be used to assess the virulence of other pathogens for which no suitable animal model of infection is still lacking.

Download Full-text

The Novel TRPA1 Antagonist BI01305834 Inhibits Ovalbumin-Induced Bronchoconstriction in Guinea Pigs

10.21203/rs.3.rs-88800/v1 ◽

2020 ◽

Author(s):

Mariska van den Berg ◽

Susan Nijboer - Brinksma ◽

Sophie Bos ◽

Maarten van den Berge ◽

David Lamb ◽

...

Keyword(s):

Pilot Study ◽

Guinea Pig ◽

Guinea Pigs ◽

Ex Vivo ◽

Optimal Dose ◽

Pig Model ◽

The Novel ◽

Airway Narrowing ◽

Guinea Pig Model

Abstract Background: We hypothesized that TRPA1 channels contribute to airway hyperresponsiveness (AHR) and inflammation in asthma. We evaluated the efficacy of the novel TRPA1 antagonist BI01305834 in a guinea pig model of asthma. Methods: First a pilot study was performed in a guinea pig model of allergic asthma to find the optimal dose of BI01305834. Next, the effect of BI01305834 on AHR to inhaled histamine after the early and late asthmatic reaction (EAR and LAR), magnitude of EAR and LAR and airway inflammation was assessed. Precision-cut lung slices and trachea strips were used to investigate the bronchoprotective and bronchodilating effect of BI01305834. Statistical evaluation of differences of in vivo data was performed using a Mann-Whitney U test or One-way nonparametric Kruskal-Wallis ANOVA, for ex vivo data One- or Two-way ANOVA was used, all with Dunnett’s post-hoc test where appropriate.Results: A dose of 1 mg/kg BI01305834 was selected based on AHR and exposure data in blood samples from the pilot study. In the subsequent study 1 mg/kg BI01305834 inhibited AHR after the EAR, and the development of EAR and LAR elicited by ovalbumin in ovalbumin-sensitized guinea pigs. BI01305834 did not inhibit allergen-induced total and differential cells in the lavage fluid and interleukin-13 gene expression in lung homogenates. Furthermore, BI01305834 was able to inhibit allergen and histamine-induced airway narrowing in guinea pig lung slices, without affecting histamine release, and reverse allergen-induced bronchoconstriction in guinea pig trachea strips.Conclusions: TRPA1 inhibition protects against AHR and the EAR and LAR in vivo and allergen and histamine-induced airway narrowing ex vivo, and reverses allergen-induced bronchoconstriction, independently of inflammation. This effect was partially dependent upon histamine, suggesting a neuronal and possible non-neuronal role for TRPA1 in allergen-induced bronchoconstriction.

Download Full-text

Estimation of a safety limit for ultraviolet radiation-B (UVR-B)-induced cataract in an in vivo pigmented guinea pig model

Acta Ophthalmologica Scandinavica ◽

10.1111/j.1600-0420.2007.01062_3079.x ◽

2007 ◽

Vol 85 ◽

pp. 0-0

Author(s):

V MODY ◽

M KAKAR ◽

X DONG ◽

Y ZHANG ◽

S HUANG ◽

...

Keyword(s):

Guinea Pig ◽

Ultraviolet Radiation ◽

Pig Model ◽

Guinea Pig Model ◽

Safety Limit ◽

Ultraviolet Radiation B

Download Full-text

672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia

Open Forum Infectious Diseases ◽

10.1093/ofid/ofz360.740 ◽

2019 ◽

Vol 6 (Supplement_2) ◽

pp. S307-S307

Author(s):

Stephen Barat ◽

Katyna Borroto-Esoda ◽

Mahmoud Ghannoum ◽

Elizabeth Berkow ◽

David A Angulo

Keyword(s):

Guinea Pig ◽

Murine Model ◽

The United States ◽

In Vitro Studies ◽

Pig Model ◽

Cutaneous Infection ◽

Candida Auris ◽

Guinea Pig Model

Abstract Background Candida auris is a growing global threat; a pathogen associated with high mortality (up to 60%), multidrug resistance, the ability to spread from person-to-person and surface-to-person, presenting high risk for outbreaks in healthcare facilities. Ibrexafungerp is a novel IV/oral glucan synthase inhibitor (triterpenoid) antifungal with activity against Candida, Aspergillus, and Pneumocystis spp., in Phase 3 development. Methods In vitro studies tested ibrexafungerp against >100 clinical isolates of C. auris. Other in vitro studies evaluated the effects of ibrexafungerp against C. auris biofilms. In vivo activity against C. auris was evaluated using a disseminated murine model and a cutaneous infection guinea pig model. In humans, an ongoing open-label trial of ibrexafungerp for treatment of patients with infections caused by C. auris (the CARES study) has been initiated in the United States and India. Results In vitro and in vivo studies demonstrated that ibrexafungerp is active against C. auris, including MDR strains. The MIC mode for ibrexafungerp was 1 μg/mL and the MIC50 and MIC90 were 0.5 and 1 μg/mL, respectively. Many echinocandin-resistant C. auris isolates have shown susceptibility to ibrexafungerp. Furthermore, ibrexafungerp has been shown to reduce biofilm thickness. In animal models of C. auris infection, treatment with ibrexafungerp resulted in improved survival and reduced fungal burden in both the murine model of disseminated infection and the guinea pig model of cutaneous infection as compared with untreated controls. In humans, two patients with difficult to treat C. auris candidemias were enrolled in the CARES study and responded positively to oral ibrexafungerp with eradication of the infection. Conclusion These data demonstrate that ibrexafungerp possess potent in vitro and in vivo activity as well as promising clinical activity. Therefore, continued clinical evaluation of ibrexafungerp as an option to treat C. auris infections is warranted. Disclosures All authors: No reported disclosures.

Download Full-text